PSTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Poseida Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $71.32
The historical data trend for Poseida Therapeutics's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poseida Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Current Liabilities | Get a 7-Day Free Trial | 21.86 | 30.03 | 43.34 | 53.89 | 71.32 |
Poseida Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Current Liabilities | Get a 7-Day Free Trial | 53.89 | 48.69 | 49.89 | 76.97 | 71.32 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Poseida Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 30.964 | + | 5.951 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 3.395 | + | 31.008 | |
= | 71.32 |
Poseida Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 30.964 | + | 5.951 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 3.395 | + | 31.008 | |
= | 71.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Poseida Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
John P. Schmid | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Luke Corning | director | 614 DAVIS STREET, EVANSTON IL 60201 |
Marcea Bland Lloyd | director | 9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
Charles M Baum | director | C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
Cynthia Collins | director | 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
Rafael Amado | director | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Kristin Yarema | officer: President, Cell Therapy | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Malin Life Sciences Holdings Ltd | 10 percent owner | 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ---- |
Eric Ostertag | director, 10 percent owner, officer: Chief Executive Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Kerry D. Ingalls | officer: Chief Operating Officer | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Brent Warner | officer: President, Gene Therapy | C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Matthew A. Spear | officer: Chief Medical Officer | C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121 |
Harry J Leonhardt | officer: GC & Chief Compliance Officer | C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
David Hirsch | director | C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Sean Murphy | director, 10 percent owner | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
From GuruFocus
By PRNewswire PRNewswire • 04-13-2023
By PRNewswire PRNewswire • 11-10-2022
By PRNewswire • 06-26-2023
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire PRNewswire • 02-08-2023
By PRNewswire • 07-05-2023
By PRNewswire PRNewswire • 03-01-2023
By PRNewswire • 08-07-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 11-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.